Skip to search formSkip to main contentSkip to account menu

L-BLP25

Known as: BLP25, BLP25 Liposome Vaccine, BP1-7-KLH 
A liposome-encapsulated peptide vaccine consists of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Cancer VaccinesMembrane Glycoproteins

Narrower (2)

Stimuvaxtecemotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
Locally-advanced non-small cell lung cancer (LA-NSCLC) is optimally treated with definitive chemoradiation or surgery in… 
2016
2016
Micro- and Nanoparticulate Cancer Vaccines: A Vision for the Future
In lieu of an abstract, here is the article's first paragraph: Formulation scientists are constantly challenged with unique… 
Review
2014
Review
2014
L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.
Lung cancer is one of the most prevalent malignancies worldwide and the leading cause of cancer-related death. Most cases are non… 
2014
2014
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
Incorporating an effective and tolerable immunotherapeutic as part of maintenance therapy for unresectable stage III non-small… 
Review
2014
Review
2014
Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy… 
Review
2014
Review
2014
Recent advances in immunotherapy for non-small-cell lung cancer
Despite of recent development in the field of molecular targeted therapies, lung cancer is a leading cause of cancer death in the… 
Review
2013
Review
2013
Locally Advanced Lung Cancer: An Optimal Setting for Vaccines and Other Immunotherapies
AbstractLung cancer has traditionally been considered relatively resistant to immunotherapies. However, recent advances in the… 
2011
2011
Randomized Phase II Study of BLP25 Liposome Vaccine (L-BLP25) in Patients with Multiple Myeloma
Abstract 2927 The standard of care for patients (pts) with asymptomatic multiple myeloma (MM) stage I/II or a stable response… 
Review
2010
Review
2010
L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study.
e13153 Background: The innovative cancer vaccine L-BLP25 (Stimuvax; BLP25 liposome vaccine) targets the MUC1 tumor-associated… 
2007
2007
A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease
3075 Background: L-BLP25 is an innovative cancer vaccine that incorporates a synthetic MUC1 lipopeptide in a liposomal delivery… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)